CIP
NVRO

Convergence Investment Partners’s NEVRO CORP. NVRO Stock Holding History

Convergence Investment Partners’s Portfolio NVRO Stock Details NVRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-300
Closed -$26K – 942
2018
Q1 		$26K Buy
+300
New +$24.2K ﹤0.01% 543

Other funds holding NVRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Convergence Investment Partners's NVRO Position: Q2 2018 in Review

Convergence Investment Partners sold out of NEVRO CORP. (NVRO) in Q2 2018, closing a stake of 300 shares — an estimated $26K sold.

Convergence Investment Partners first reported a position in NVRO in Q1 2018 and held it in 1 quarter. The position peaked at $26K in Q1 2018. 192 funds tracked by Wall St. Rank hold NVRO as of Q2 2018.

  • Convergence Investment Partners reported no remaining NEVRO CORP. position as of Q2 2018 after selling out during the quarter.
  • Convergence Investment Partners sold 300 NEVRO CORP. shares in Q2 2018, an estimated $26K.
  • Convergence Investment Partners first reported a position in NEVRO CORP. in Q1 2018 and held it in 1 quarter.
  • Convergence Investment Partners's NEVRO CORP. position peaked at $26K in Q1 2018.
  • 192 funds tracked by Wall St. Rank held NEVRO CORP. as of Q2 2018.

Based on Convergence Investment Partners's 13F filing for Q2 2018, filed 7 Aug 2018.